Literature DB >> 18680473

Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.

J M Ladero1.   

Abstract

Polymorphic N-acetyl transferases (NAT) 1 and 2 are involved in detoxification of xenobiotic arylamines and hydralazines. These common environmental chemicals may be related to the pathogenesis of many spontaneous disorders, mainly malignancies, but also disimmune or degenerative diseases, for which a polygenic predisposition has been suggested. Hence, polymorphic NAT genes (NAT2 has been the most studied one) may be low-penetrance risk genes for some of these disorders. Although a relation of risk may be definitely discarded for systemic lupus erythematosus (SLE), inflammatory bowel disease and endometriosis, more research is needed for rheumatoid arthritis, Parkinson's, Alzheimer's, Behçet's and periodontal diseases , as current results are inconclusive but suggest a possible relation with NAT2 polymorphism. In diabetes mellitus the possible relation with the rapid phenotype may be due to acquired metabolic changes and more genotyping studies are needed. NAT2 slow metabolizers are more prone to the side effects of polymorphically acetylated drugs, as is the SLE-like syndrome induced by hydralazine and procainamide, the side effects due to sulphasalazine and the skin rash secondary to many sulphonamides. Future research should be based on well-designed studies, with adequate sample sizes and homogeneous recruitment criteria, to obviate the proliferation of small studies that are time- and resource-consuming without offering definite answers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680473     DOI: 10.2174/138920008784892038

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  11 in total

1.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

Review 2.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

3.  Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data.

Authors:  Audrey Sabbagh; Pierre Darlu; Michel Vidaud
Journal:  BMC Med Genet       Date:  2009-12-31       Impact factor: 2.103

4.  Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey.

Authors:  Audrey Sabbagh; Pierre Darlu; Brigitte Crouau-Roy; Estella S Poloni
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

5.  The role of N-acetyltransferase 2 polymorphism in the etiopathogenesis of inflammatory bowel disease.

Authors:  M Baranska; R Trzcinski; A Dziki; M Rychlik-Sych; M Dudarewicz; J Skretkowicz
Journal:  Dig Dis Sci       Date:  2011-02-15       Impact factor: 3.199

6.  Is NAT2 Gene Polymorphism Associated with Vitiligo?

Authors:  Daya Shankar Lal Srivastava; Kamal Aggarwal; Gajendra Singh
Journal:  Indian J Dermatol       Date:  2020 May-Jun       Impact factor: 1.494

Review 7.  Sulfonamide Hypersensitivity.

Authors:  Timothy G Chow; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-01       Impact factor: 8.667

8.  Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection.

Authors:  Audrey Sabbagh; Julie Marin; Charlotte Veyssière; Emilie Lecompte; Sotiria Boukouvala; Estella S Poloni; Pierre Darlu; Brigitte Crouau-Roy
Journal:  BMC Evol Biol       Date:  2013-03-07       Impact factor: 3.260

9.  Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Pharmgenomics Pers Med       Date:  2010-03-30

10.  NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.

Authors:  Recep Dursun; Hatice Gül Dursun; Ayşe Gül Zamani; Mahmut Selman Yıldırım; İlknur Çınar
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.